We therefore hypothesize that elevated FGD3 expression in breast cancers may be correlated with better patient outcomes because FGD3 both enhances NK cell-mediated cell lysis and increases the effectiveness of doxorubicin and other lytic cell death-inducing anticancer therapies. This evidence concerns the gene FGD3 and breast carcinoma.